Riesgo tromboembólico en pacientes que han superado la infección por SARS-CoV-2

  1. Enrique González Revuelta 1
  2. Héctor Lago Gancedo 1
  3. Borja Camacho Montes 2
  4. Sofía Leiva 1
  5. Marta Iglesias Vela 3
  6. Jesús Seco Calvo 4
  1. 1 Medicina de Familia y Comunitaria. G.A.P. León, España. Grupo de trabajo SEMESMIR-Castilla y León, España.
  2. 2 Medicina de Familia y Comunitaria. G.A.P. León, España.
  3. 3 Servicio de Urgencias. Complejo Asistencial Universitario de León, España.
  4. 4 Instituto de Biomedicina (IBIOMED). Universidad de León, España.
Revista Española de Urgencias y Emergencias

ISSN: 2951-6552 2951-6544

Year of publication: 2023

Volume: 2

Issue: 1

Pages: 19-23

Type: Article


BACKGROUND. SARS-CoV-2 infection is associated with a high incidence of thromboembolic complications. However, whether or not a prothrombotic state persists after recovery is unknown. MATERIAL AND METHODS. We undertook a case-control comparison of records from November 1, 2020, to March 31, 2021. Case records for patients treated for thromboembolic episodes in hospital emergency departments were selected; control patients were treated for other conditions in the same period. We recorded whether or not case and control patients had a history of recovery from COVID-19. Bivariate logistic regression was used to explore risk. RESULTS. Records for 179 cases and 390 controls were selected. A majority of case patients had cerebrovascular stroke (30.2%) or acute coronary syndrome (21.2%). Only 17 cases (9.5%) and 390 controls (8.9%) had recently recovered from COVID-19. These data suggest an odds ratio of 1.064 (95% CI, 0.58-1.96) for COVID-19 exposure as a predictor of thromboembolic episodes, although the model was underpowered (R2 = 0.028). The effect size was small for all variables, although the effect size for severity of SARS-CoV-2 infection was higher (0.2). CONCLUSIONS. Our findings show that patients who have recovered from COVID-19 do not have a significantly higher risk of thromboembolic events than patients who have not recently recovered from this infection. Patients with a recent history of COVID-19 do not need to receive preventive anticoagulant treatment for longer periods than other patients.